Biotech Values

[DewDiligence]

LLY acquires private molecular-imaging company, Avid, for $300M up-front and $500M in contingent milestones:

http://finance.yahoo.com/news/Lilly-to-Acquire-Avid-prnews-3969511230.html?x=0&.v=1

Avid’s claim to fame is Florbetapir, an imaging agent used with PET scans to detect the beta-amyloid plaques in Alzheimer’s disease.